KiroTAC

Drug Profile

KiroTAC

Latest Information Update: 10 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kiromic
  • Class Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 10 Aug 2016 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route) prior to August 2016
  • 10 Aug 2016 Preclinical trials in Breast cancer in USA (unspecified route) prior to August 2016
  • 10 Aug 2016 Preclinical trials in Non-small cell lung cancer in USA (unspecified route) prior to August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top